RESUMEN
A divergent synthesis of (2E,4E,8E,10E)- and (2E,4E,8E,10Z)-N-isobutyldodeca-2,4,8,10-tetraenamides from pent-4-yn-1-ol allowed identification of the (2E,4E,8E,10Z)-isomer for the first time in Echinacea species. A short, stereoselective synthesis of the (2E,4E,8E,10Z)-isomer is also described which allowed further biological evaluation of this material, and the demonstration that this isomer does not occur in Spilanthes mauritiana as previously reported.
Asunto(s)
Echinacea/química , Preparaciones de Plantas/química , Alcamidas Poliinsaturadas/química , Receptor Cannabinoide CB2/metabolismo , Estructura Molecular , Plantas Medicinales/química , Alcamidas Poliinsaturadas/síntesis química , Alcamidas Poliinsaturadas/aislamiento & purificación , Receptor Cannabinoide CB2/química , Especificidad de la Especie , EstereoisomerismoRESUMEN
Haloperidol (HP) has been reported to undergo cytochrome P450 (P450)-mediated metabolism to potentially neurotoxic pyridinium metabolites; however, the chemical pathways and specific enzymes involved in these reactions remain to be identified. The aims of the current study were to (i) fully identify the cytochrome P450 enzymes capable of metabolizing HP to the pyridinium metabolite, 4-(4-chlorophenyl)-1-(4-fluorophenyl)-4-oxobutylpyridinium (HPP(+)), and reduced HP (RHP) to 4-(4-chlorophenyl)-1-(4-fluorophenyl)-4-hydroxybutylpyridinium (RHPP(+)); and (ii) determine whether 4-(4-chlorophenyl)-1-(4-fluorophenyl)-4-oxobutyl-1,2,3,6-tetrahydropyridine (HPTP) and 4-(4-chlorophenyl)-1-(4-fluorophenyl)-4-hydroxybutyl-1,2,3,6-tetrahydropyridine (RHPTP) were metabolic intermediates in these pathways. In vitro studies were conducted using human liver microsomal preparations and recombinant human cytochrome P450 enzymes (P450s 1A1, 1A2, 1B1, 2A6, 2B6, 2C9, 2C19 2D6, 2E1, 3A4, 3A5, and 3A7) expressed in bicistronic format with human NADPH cytochrome P450 reductase in Escherichia coli membranes. Pyridinium formation from HP and RHP was highly correlated across liver preparations, suggesting the same enzyme or enzymes were responsible for both reactions. Cytochrome P450s 3A4, 3A5, and 3A7 were the only recombinant enzymes which demonstrated significant catalytic activity under optimized conditions, although trace levels of activity could be catalyzed by NADPH-P450 reductase alone. NADPH-P450 reductase-mediated activity was inhibited by reduced glutathione but not catalase or superoxide dismutase, suggesting O(2)-dependent oxidation. No evidence was obtained to support the contention that HPTP and RHPTP are intermediates in these pathways. K(m) values for HPP(+) (34 +/- 5 microM) and RHPP(+) (64 +/- 4 microM) formation by recombinant P450 3A4 agreed well with those obtained with human liver microsomes, consistent with P450 3A4 being the major catalyst of pyridinium metabolite formation in human liver.
Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Haloperidol/metabolismo , Microsomas Hepáticos/enzimología , Compuestos de Piridinio/metabolismo , Biotransformación , Catálisis , Sistema Enzimático del Citocromo P-450/química , Sistema Enzimático del Citocromo P-450/genética , Haloperidol/química , Humanos , Modelos Biológicos , Mutación , Oxidación-Reducción , Compuestos de Piridinio/química , Proteínas Recombinantes/metabolismoRESUMEN
T cell-mediated destruction of the myelin sheath causes inflammatory damage of the CNS in multiple sclerosis (MS). The major T and B cell responses in MS patients who are HLA-DR2 (about two-thirds of MS patients) react to a region between residues 84 and 103 of myelin basic protein (1 ). The crystal structure of HLA-DR2 complexed with myelin basic protein(84-102) confirmed that Lys(91) is the major TCR contact site, whereas Phe(90) is a major anchor to MHC and binds the hydrophobic P4 pocket (2 ). We have tested peptides containing repetitive 4-aa sequences designed to bind critical MHC pockets and to interfere with T cell activation. One such sequence, EYYKEYYKEYYK, ameliorates experimental autoimmune encephalomyelitis in Lewis rats, an animal model of MS.
Asunto(s)
Encefalomielitis Autoinmune Experimental/inmunología , Antígenos de Histocompatibilidad/metabolismo , Péptidos/inmunología , Receptores de Antígenos de Linfocitos T/metabolismo , Adyuvantes Inmunológicos/farmacología , Secuencia de Aminoácidos , Animales , Sitios de Unión/genética , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Femenino , Antígeno HLA-DR2/metabolismo , Antígenos de Histocompatibilidad Clase II/metabolismo , Humanos , Modelos Moleculares , Datos de Secuencia Molecular , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/inmunología , Proteína Básica de Mielina/genética , Proteína Básica de Mielina/inmunología , Proteína Básica de Mielina/farmacología , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/farmacología , Péptidos/genética , Péptidos/farmacología , Ratas , Ratas Endogámicas Lew , Homología de Secuencia de Aminoácido , Linfocitos T/inmunologíaRESUMEN
The reason for differences in rate of cognitive decline in AD is unknown. The interleukin-1 alpha (IL-1 alpha) -889 *2 allele is associated with increased risk for AD. Surprisingly, in a sample of 114 patients followed for an average of 3.8 years, individuals homozygous for the IL-1 alpha -889 *1 allele declined significantly more rapidly on the Mini-Mental State Examination than did others. There was no difference in rate of decline between patients with and without the APOE epsilon 4 allele. These results support the hypothesis that inflammation is important in the clinical course of AD.
Asunto(s)
Enfermedad de Alzheimer/genética , Trastornos del Conocimiento/genética , Interleucina-1/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Enfermedad de Alzheimer/inmunología , Trastornos del Conocimiento/inmunología , Progresión de la Enfermedad , Femenino , Genotipo , Humanos , Masculino , Polimorfismo GenéticoRESUMEN
The development of bicistronic systems for coexpression of recombinant human cytochrome P450 enzymes (P450s) with their redox partner, NADPH-cytochrome P450 reductase (NPR), has enabled P450 activity to be reconstituted within bacterial cells. During expression of recombinant P450 2E1 and some other forms, we observed the formation of a blue pigment in bacterial cultures. The pigment was extracted from cultures and shown to comigrate with standard indigo on TLC. UV-visible spectroscopy and mass spectrometric analysis provided further support for identification of the pigment as indigo. Indigo is known to form following the spontaneous oxidation of 3-hydroxyindole. Accordingly, we speculated that indole, formed as a breakdown product of tryptophan in bacteria, was hydroxylated by the P450 system, leading to indigo formation. Bacterial membranes containing recombinant P450 2E1 and human NPR were incubated in vitro with indole and shown to catalyze formation of a blue pigment in a time- and cofactor-dependent manner. These studies suggest potential applications of mammalian P450 enzymes in industrial indigo production or in the development of novel colorimetric assays based on indole hydroxylation.